- Parties “have settled the case in principle” and asked for time to complete settlement, according to
lettersent Tuesday to judge in federal court in Wilmington, Delaware
- Patents, owned by Columbia and exclusively licensed to Qiagen, are related to using modified versions of nucleotides to sequence DNA,
- The nucleotide analogues, as the modified versions are called, are useful in next-generation sequencing, important in the emerging field of personalized precision medicine
- CASE: Trustees of Columbia University in the City of New York ...
June 9, 2021, 3:10 PM